Helsinn Therapeutics

AKYNZEO

Manufacturer:

Helsinn Therapeutics

Akynzeo HCPCS:

J1454

HCPCS Code Descriptor:

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Category:

J Code

Akynzeo NDCs:

69639-0106-01, 69639-0105-01, 69639-0102-01

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Akynzeo:

AKYNZEO is an Oncology-Anti-Emetic drug manufactured by Helsinn Therapeutics and administered via the Intravenous route of administration. The J Code: J1454 is aligned to the drug AKYNZEO.

AKYNZEO is an antiemetic that may treat acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. It is adminstered intravenously and is commonly used with dexamethasone. AKYNZEO (J1454) is composed of neupitant and palonosetron. Fosnetupitant works by selectively binding neurokinin-1 receptors, whose activation are largely associated with delayed emesis. Palonosetron acts as a 5-HT3 receptor antagonist and prevents activation of 5-HT3 recpetors by serotonin, which is largely associated with acute emesis. AKYNZEO is contraindicated for pregnant women, patients with severe hepatic and renal issues, and patients taking CYP3A4 substrates or inducers. Patient assistance for this medication is available through the Helsinn Cares program.

ACCESS PRICING AND MORE BY REGISTERING

J1454 Added Date:

January 1, 2019

J1454 Effective Date:

January 1, 2019

J1454 Termination Date:

HCPCS Active

Akynzeo billing and coding information can be found through Helsinn Therapeutics at the link below:
Akynzeo patient assistance information can be found through Helsinn Cares at the URL: https://helsinnreimbursement.com/
AKYNZEO prescribing information can be found at the link below:
Information regarding AKYNZEO’s side effects can be found at MedlinePlus